O
KYTH

OrbiMed’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

OrbiMed’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-947,900
Closed -$47.5M – 158
2015
Q1 		$47.5M Buy
947,900
+225,000
+31% +$9.44M 0.41% 58
2014
Q4 		$25.1M Buy
+722,900
New +$25.2M 0.24% 67

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's KYTH Position: Q2 2015 in Review

OrbiMed sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q2 2015, closing a stake of 947,900 shares — an estimated $47.5M sold.

OrbiMed first reported a position in KYTH in Q4 2014 and held it in 2 quarters. The position peaked at $47.5M in Q1 2015. 153 funds tracked by Wall St. Rank hold KYTH as of Q2 2015.

  • OrbiMed reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q2 2015 after selling out during the quarter.
  • OrbiMed sold 947,900 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q2 2015, an estimated $47.5M.
  • OrbiMed first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2014 and held it in 2 quarters.
  • OrbiMed's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $47.5M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.